Back to top
more

Hyperfine (HYPR)

(Delayed Data from NSDQ)

$0.87 USD

0.87
532,608

0.00 (-0.20%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $0.86 -0.01 (-0.93%) 5:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 247)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hyperfine, Inc. (HYPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of -10.00% and +1.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Electromed, Inc. (ELMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Electromed (ELMD) delivered earnings and revenue surprises of +13.64% and +1.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hyperfine (HYPR) Upgraded to Buy: Here's Why

by Zacks Equity Research

Hyperfine (HYPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and -7.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of -9.09% and -22.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Treace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of +3.45% and +0.79%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Delcath Systems (DCTH) delivered earnings and revenue surprises of +250.00% and +9.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System

by Zacks Equity Research

HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.

Zacks Equity Research

Hyperfine, Inc. (HYPR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 27.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TransMedics (TMDX) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 141.38% and 16.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?